pancreat
adenocarcinoma
fourth
lead
caus
cancer
death
overal
surviv
less
ampl
evid
pancreat
adenocarcinoma
elicit
antitumor
immun
respons
identif
pancreat
cancerassoci
antigen
spur
develop
vaccinationbas
strategi
treatment
promis
result
observ
anim
tumor
model
clinic
studi
found
limit
success
trial
perform
patient
advanc
pancreat
cancer
contribut
immun
suppressor
mechan
taken
account
articl
detail
recent
work
tumor
antigen
vaccin
recent
identifi
mechan
immun
suppress
pancreat
cancer
offer
perspect
increas
clinic
efficaci
vaccin
pancreat
cancer
pancreat
adenocarcinoma
henceforth
indic
pancreat
cancer
account
major
pancreat
cancer
poorest
outcom
pancreat
cancer
highli
aggress
fourth
lead
caus
cancer
death
usa
estim
new
case
prognosi
patient
dismal
overal
surviv
less
median
surviv
month
time
diagnosi
patient
present
oper
diseas
wherea
approxim
found
local
advanc
unresect
diseas
approxim
metastat
diseas
surgic
resect
known
cur
treatment
pancreat
cancer
howev
even
complet
surgic
resect
recurr
common
major
patient
recur
distant
metastasi
patient
develop
recurr
usual
present
month
resect
median
surviv
surgeri
month
surviv
rate
approxim
median
surviv
patient
local
advanc
unresect
diseas
month
signific
malign
illustr
compar
estim
death
pancreat
cancer
death
prostat
breast
cancer
respect
poor
prognosi
pancreat
cancer
relat
combin
late
detect
patient
present
local
advanc
metastat
diseas
standard
care
consist
rel
ineffect
chemotherapeut
regimen
gemcitabin
current
approv
chemotherapeut
agent
choic
treatment
patient
pancreat
cancer
adjuv
chemoradi
consid
standard
care
mani
postop
pancreat
cancer
patient
treat
north
america
multipl
promis
drug
target
hallmark
cancer
angiogenesi
prolifer
metastasi
fail
provid
clinic
relev
benefit
immunebas
treatment
cancer
repres
rapidli
evolv
therapi
great
potenti
base
supposit
immun
system
discrimin
tumor
normal
self
investig
pursu
immunebas
treatment
cancer
year
past
year
larg
bodi
data
accumul
show
cancer
patient
gener
b
cell
recogn
antigen
express
autolog
pancreat
tumor
cell
addit
evid
obtain
anim
model
show
mice
defici
gene
associ
immun
eg
ifn
perforin
prone
develop
cancer
furthermor
extens
analysi
immun
infiltr
human
tumor
demonstr
posit
correl
prognosi
presenc
humor
respons
pancreat
tumor
antigen
mesothelin
tumorinfiltr
cytotox
cell
cell
contrast
mous
model
activ
kra
mutat
express
pancrea
preinvas
pancreat
lesion
character
infiltr
immun
suppressor
cell
rather
immun
effector
cell
suggest
tumor
immun
may
block
incept
pancreat
cancer
develop
mice
kra
mutat
develop
pancreat
adenocarcinoma
eventu
die
diseas
final
find
antagon
neg
tcell
regul
cytotox
tlymphocyteassoci
ctla
band
tlymphocyt
attenu
btla
augment
antitumor
immun
respons
confirm
patient
mount
immun
respons
tumor
despit
mount
evid
antitumor
immun
respons
elicit
cancer
patient
respons
ineffect
result
elimin
tumor
given
tumor
antigen
selfor
mutat
selfantigen
pancreat
tumor
microenviron
immunosuppress
discuss
length
surpris
particular
note
find
preval
treg
peripher
blood
tumor
express
level
program
ligand
tumor
independ
predictor
poor
surviv
pancreat
cancer
treg
constitut
cell
induc
immun
toler
suppress
host
immun
respons
selfand
nonselfantigen
thu
play
critic
role
toler
immun
respons
malign
find
strengthen
notion
pancreat
cancer
induc
antitumor
immun
respons
thu
effort
toward
improv
clinic
efficaci
immun
therapi
involv
strategi
neutral
overcom
immun
suppress
discuss
articl
preclin
clinic
effort
toward
immun
therapi
pancreat
cancer
molecular
identif
human
tumor
antigen
earli
opportun
specif
sensit
immun
cell
tumor
antigen
becam
realiti
lead
multitud
experiment
strategi
immunebas
therapi
cancer
multipl
clinic
studi
document
evid
treatmentinduc
antigenspecif
immun
respons
protect
immun
respons
observ
patient
metastat
diseas
despit
setback
renew
optim
immun
therapi
vaccin
postsurgeri
patient
minim
diseas
shown
impact
breast
pancreat
cancer
addit
vaccin
tumor
antigen
attract
approach
adjuv
treatment
postsurgeri
tumorinduc
immun
suppress
minim
consid
ideal
tumor
vaccin
candid
express
antigen
mutat
unalt
self
must
restrict
tumor
minim
express
elsewher
bodi
follow
section
restrict
discuss
short
list
tumor
antigen
fit
criterion
pancreat
cancer
tabl
use
immunolog
adjuv
discuss
focus
recent
exampl
pancreat
cancer
studi
either
murin
human
whenev
possibl
articl
tumor
antigen
target
discuss
greater
extent
other
reflect
quantiti
report
literatur
tabl
list
number
clinic
trial
involv
pancreat
cancer
patient
repres
multipl
differ
vaccin
platform
figur
discuss
follow
section
simplest
vaccin
approach
appli
cancer
inocul
individu
irradi
tumor
cell
approach
mani
advantag
specif
tumor
antigen
need
identifi
character
prior
vaccin
immun
respons
multipl
tumor
antigen
gener
may
protect
tumor
escap
variant
vaccin
limit
patient
hla
background
owe
crosspresent
tumor
antigen
uptak
dendrit
cell
dc
particularli
advantag
tumor
cell
line
readili
avail
avail
autolog
tumor
cell
may
restrict
tumor
cell
vaccin
platform
easili
modifi
exampl
tumor
cell
transduc
express
immunomodulatori
cytokin
granulocyt
macrophag
colonystimul
factor
gmcsf
perform
jaffe
et
al
phase
clinic
trial
studi
pancreat
tumor
cell
vaccin
induc
tcell
respons
specif
mesothelin
regardless
hla
match
tumor
vaccin
recipi
demonstr
crossprim
occur
mesothelin
particularli
promis
cancer
vaccin
target
owe
low
level
express
nontumor
tissu
high
level
express
pancreat
well
cancer
ie
ovarian
phase
ii
trial
vaccin
ongo
patient
resect
pancreat
cancer
tumor
cell
vaccin
also
modifi
express
epitop
increas
antibodymedi
uptak
dc
normal
express
tumor
immunogen
owe
overexpress
tumorrestrict
hypoglycosyl
newlink
genet
corpor
ia
usa
develop
wholecel
vaccin
express
modifi
express
epitop
focu
multipl
clinic
trial
vaccin
take
advantag
antibodi
found
peopl
due
exposur
gastrointestin
flora
result
increas
uptak
vaccin
antibodydepend
manner
murin
studi
addit
epitop
pancreat
cancer
wholecel
vaccin
result
increas
product
anti
antibodi
enhanc
tumorspecif
tcell
respons
increas
surviv
challeng
peptid
correspond
immunogen
tumor
antigen
antigen
epitop
administ
cancer
vaccin
mani
design
enhanc
tcell
respons
import
respons
elimin
tumor
peptid
vaccin
requir
manipul
patient
tissu
whose
avail
may
limit
number
peptid
vaccin
success
use
produc
antigenspecif
respons
pancreat
cancer
patient
phase
studi
vaccin
peptid
extracellular
tandem
repeat
gener
tcell
respons
patient
resect
local
advanc
pancreat
cancer
two
patient
aliv
month
separ
phase
clinic
trial
use
peptid
vaccin
product
circul
antibodi
detect
patient
inoper
pancreat
biliari
cancer
although
signific
impact
surviv
discov
telomerasebas
vaccin
consist
human
telomeras
revers
transcriptas
also
known
peptid
found
induc
telomerasespecif
immun
respons
evalu
patient
measur
dth
nonresect
pancreat
cancer
posit
dth
found
live
longer
posit
dth
recent
phase
iii
clinic
trial
perform
effect
gemcitabin
treatment
surviv
compar
gemcitabin
treatment
combin
therapi
unresect
metastat
pancreat
cancer
patient
howev
trial
termin
surviv
benefit
found
similar
studi
vegf
receptor
vegfr
peptid
epitop
vaccin
administ
gemcitabin
patient
advanc
pancreat
cancer
total
patient
receiv
vaccin
antigenspecif
dth
cell
detect
vaccin
median
overal
surviv
time
month
random
placebocontrol
multicent
phase
iiiii
studi
peptid
vaccin
therapi
combin
gemcitabin
current
underway
patient
unresect
advanc
recurr
pancreat
cancer
excit
result
come
studi
krastarget
peptid
vaccin
pilot
vaccin
studi
pancreat
colorect
patient
vaccin
kra
peptid
contain
patientspecif
mutat
three
five
pancreat
cancer
patient
display
antigenspecif
immun
respons
kra
diseas
progress
observ
two
pancreat
cancer
patient
respond
vaccin
respond
evid
diseas
pancreat
cancer
patient
mean
diseasefre
surviv
month
mean
overal
surviv
month
observ
longerterm
studi
patient
follow
year
surgic
resect
pancreat
adenocarcinoma
vaccin
kra
peptid
vaccin
administ
concomitantli
gmcsf
remark
patient
receiv
vaccin
still
aliv
time
point
immunolog
test
show
memori
tcell
respons
still
present
survivor
result
peptid
vaccin
highli
encourag
increas
immunogen
peptid
vaccin
group
mutat
key
anchor
residu
peptid
bind
mhci
molecul
increas
therefor
present
cell
also
increas
especi
import
vaccin
tumor
self
epitop
often
weak
intermedi
binder
hla
molecul
murin
model
pancreat
cancer
group
found
strategi
increas
surviv
appli
peptid
vaccin
deriv
murin
mesothelin
hamilton
n
hawkin
wg
unpublish
data
similarli
peptid
vaccin
modifi
way
shown
enhanc
product
patient
normal
donor
cell
tcell
clone
gener
via
stimul
peptid
could
lyse
target
puls
nativ
epitop
well
human
tumor
cell
vitro
remark
one
case
report
vaccin
modifi
survivin
peptid
result
remiss
liver
metastasi
one
individu
pancreat
cancer
altern
method
enhanc
present
peptid
link
antibodi
peptid
target
dc
exampl
antimurin
antibodi
fuse
either
human
mesothelin
survivin
shown
enhanc
immun
respons
direct
deliveri
tumor
antigen
activ
dc
murin
studi
similarli
tat
protein
hiv
facilit
entri
cell
fuse
antigen
order
enhanc
uptak
dc
howev
techniqu
use
mainli
introduc
antigen
carcinoembryon
antigen
cea
dc
peptid
vaccin
alon
anoth
proteinbas
vaccin
approach
util
antiidiotyp
vaccin
mimic
tumor
antigen
cea
murin
monoclon
success
use
gener
anticea
humor
tcell
respons
result
reject
ceaexpress
tumor
murin
model
colon
cancer
two
phase
ii
trial
involv
complet
lung
colorect
cancer
although
result
yet
publish
recent
effort
made
gener
person
peptid
vaccin
base
tumorantigen
epitop
immunogen
particular
patient
yanagimotto
et
al
appli
approach
combin
gemcitabin
therapi
pancreat
cancer
phase
clinic
trial
prior
vaccin
cell
patient
pbmc
screen
panel
tumor
antigenderiv
peptid
patient
vaccin
peptid
respons
increas
tumor
antigenspecif
tcell
respons
observ
evalu
patient
correl
clinic
respons
humor
respons
post
vaccin
although
patient
experienc
either
reduct
tumor
size
median
surviv
time
month
group
publish
similar
phase
ii
studi
found
median
surviv
time
month
surviv
specif
tumor
antigen
known
dna
vaccin
util
dna
vaccin
administ
human
via
intramuscular
inject
without
electropor
techniqu
allow
immun
respons
multipl
potenti
epitop
within
antigen
gener
regardless
recipi
mhc
profil
pancreat
cancer
studi
dna
vaccin
mainli
appli
murin
model
cancer
though
ongo
clinic
trial
cancer
one
murin
pancreat
cancer
studi
vaccin
either
murin
human
fulllength
survivin
dna
gener
antitumor
specif
respons
increas
infiltr
tumor
lymphocyt
increas
surviv
similar
result
found
studi
dna
vaccin
use
prevent
therapeut
vaccin
pancreat
cancer
model
murin
ovarian
cancer
model
fulllength
human
mesothelin
dna
vaccin
also
shown
inhibit
growth
human
mesothelinexpress
tumor
enhanc
surviv
induc
tcell
tcell
humor
respons
likewis
oral
dna
vaccin
either
fulllength
extracellular
domain
region
result
decreas
tumor
size
intratumor
microvessel
densiti
liver
metastas
murin
colon
cancer
studi
increas
surviv
time
antibodi
also
observ
serum
vaccin
dna
vaccin
also
use
express
encod
cea
link
thelper
epitop
tetanu
toxin
vaccin
skew
respons
phenotyp
increas
product
ceaspecif
cell
boost
either
cea
peptid
repeat
dna
vaccin
mice
howev
studi
tumor
challeng
publish
vaccin
highli
engin
molecul
singlechain
trimer
sct
also
express
dna
vaccin
hla
sct
consist
hla
heavi
chain
peptid
interest
connect
flexibl
linker
region
figur
introduc
via
dna
vaccin
sct
bypass
antigen
process
lead
direct
express
encod
hlapeptid
complex
cell
surfac
express
stabl
endogen
hlapeptid
compound
allow
increas
stimul
antigen
specif
cell
sct
ideal
platform
present
tumor
antigen
cell
fact
sct
dna
vaccin
util
multipl
viral
tumor
target
shown
vivo
murin
studi
effect
dna
vaccin
compar
peptid
cdna
vaccin
exampl
hung
et
al
administ
dna
vaccin
encod
sct
present
human
mesothelin
peptid
mice
transgen
express
ovarian
cancer
model
mesothelin
specif
tcell
respons
gener
tumorfre
surviv
enhanc
compar
vaccin
ovasct
howev
mice
use
toler
foreign
human
mesothelin
peptid
present
sct
make
data
less
translat
relev
recent
sct
platform
improv
upon
peptid
bind
hla
molecul
interact
enhanc
addit
pantcel
helper
epitop
padr
includ
sct
dna
vaccin
sct
vaccin
present
west
nile
viru
peptid
show
increas
surviv
west
nile
virusinfect
transgen
mice
improv
sct
platform
show
great
promis
current
develop
test
patient
breast
cancer
institut
addit
tradit
ie
peptidebas
vaccin
modal
group
util
variou
properti
microorgan
virus
enhanc
vaccin
microorgan
use
essenti
antigen
deliveri
system
also
ad
benefit
act
adjuv
stimul
innat
immun
respons
though
engag
pattern
recognit
receptor
tolllik
receptor
tlr
number
group
use
viru
deliv
pancreat
cancer
associ
antigen
test
murin
model
andor
clinic
trial
exampl
one
group
use
viru
scaffold
display
administr
result
robust
immun
respons
delay
growth
tumor
mice
transgen
human
howev
viral
base
vaccin
design
deliv
transgen
enabl
infect
cell
produc
tumor
antigen
interest
adenoviru
use
way
deliv
cea
found
decreas
tumor
volum
mice
bear
ceaexpress
tumor
human
clinic
trial
pox
virusbas
approach
deliv
tumor
antigen
well
costimulatori
molecul
use
kaufman
et
al
complet
phase
studi
pancreat
cancer
patient
vaccin
via
vaccinia
viru
panvacv
express
cea
peptid
peptid
three
costimulatori
molecul
also
known
tricom
gmcsf
administ
adjuv
addit
vaccin
fowlpox
viru
panvacf
express
molecul
also
administ
antigenspecif
antibodi
respons
discov
ten
patient
antigenspecif
tcell
respons
found
five
eight
patient
test
increas
surviv
seen
gener
immun
respons
similarli
mors
et
al
gener
alphaviru
vector
express
cea
packag
viruslik
particl
term
cea
vrp
alphaviru
chosen
preferenti
infect
dc
although
one
pancreat
cancer
patient
includ
studi
liver
metastasi
individu
remark
resolv
vaccin
lentivir
system
also
gener
specif
target
dc
shown
inhibit
tumor
growth
murin
tumor
model
howev
viru
use
vaccin
pancreat
tumor
antigen
util
pancreat
cancer
model
clinic
studi
heatkil
yeast
transfect
tumor
antigen
shown
activ
dc
use
vaccin
murin
model
remondo
et
al
show
saccharomyc
cerevisia
sc
express
cea
transgen
activ
human
dc
success
activ
ceaspecif
tcell
clone
tcell
clone
abl
lyse
human
cea
pancreat
tumor
line
murin
studi
vaccin
sccea
result
gener
ceaspecif
cell
reduc
tumor
volum
increas
surviv
vaccin
hceatransgen
mice
challeng
ceaexpress
tumor
compar
ceapox
vaccin
platform
similar
level
ceaspecif
cell
gener
respons
sccea
howev
tcell
receptor
tcr
repertoir
differ
specif
avid
author
suggest
take
advantag
divers
vaccin
modal
although
perform
human
yet
murin
carcinogeninduc
lung
tumor
model
sc
use
vaccin
kra
result
tumor
regress
bacteria
also
use
vaccin
popular
intracellular
facult
bacteria
listeria
monocytogen
lm
salmonella
enterica
serovar
typhimurium
st
bacteria
advantag
inexpens
gener
easili
attenu
kill
antibiot
need
lm
infect
phagocyt
cell
uniqu
abil
escap
phagosom
live
intracellularli
therefor
liveattenu
lm
deliv
protein
mrna
cdna
interest
directli
cytosol
antigenpres
cell
macrophag
platform
appli
human
mesothelin
result
mesothelinspecif
tcell
respons
mice
cynomolgu
monkey
therapeut
effect
tumorbear
mice
recent
phase
clinic
trial
found
lmbase
mesothelinexpress
vaccin
well
toler
lm
vaccin
express
appli
murin
breast
cancer
model
show
antigenspecif
tcell
respons
decreas
tumor
growth
similar
lm
st
infect
phagocyt
cell
evad
lysi
block
fusion
phagosom
lysosom
work
focus
develop
oral
stbase
dna
vaccin
one
vaccin
deliv
cea
dna
shown
prevent
growth
lung
carcinoma
cea
transgen
mice
similarli
dna
vaccin
result
complet
reject
ceaexpress
colon
carcinoma
murin
studi
addit
type
iii
secret
system
st
util
deliv
protein
antigen
directli
cytosol
antigenpres
cell
strategi
use
vaccin
survivin
murin
model
antitumor
immun
respons
tumor
observ
humor
immun
respons
tumor
antigen
mesothelin
found
favor
prognost
factor
pancreat
cancer
anticanc
effect
antibodi
thought
primarili
mediat
via
antibodydepend
cell
cytotox
adcc
although
complementmedi
lysi
may
contribut
number
group
gener
monoclon
antibodi
cell
surfac
tumor
antigen
mesothelin
cea
addit
adcc
antibodi
link
immunotoxin
result
direct
kill
tumor
cell
intern
link
radioisotop
use
radiopharmaceut
restrict
discuss
antibodi
direct
antigen
extens
studi
vaccin
target
tabl
antibodi
target
block
angiogensi
bevacizumab
discuss
number
antibodi
mesothelin
studi
mous
human
exampl
murin
singlechain
fv
specif
human
mesothelin
link
pseudomona
exotoxin
pe
result
cell
death
via
inhibit
intern
phase
clinic
studi
found
well
toler
administr
version
releas
pegyl
result
complet
regress
mesothelinexpress
human
carcinoma
mice
singl
dose
mousehuman
chimer
monoclon
antibodi
util
fv
shown
elicit
adcc
mesothelinposit
cell
combin
gemcitabin
reduc
tumor
growth
nude
mice
compar
either
treatment
alon
advers
effect
nonhuman
primat
two
fulli
human
antihuman
mesothelin
antibodi
develop
bind
mesothelinposit
cell
result
lysi
via
adcc
similar
fuse
truncat
pea
immunotoxin
although
bind
site
mesothelin
probabl
bind
distinct
overlap
epitop
mani
anticea
antibodi
gener
bulk
studi
radioimmunotherapi
cover
scope
articl
howev
number
anticea
antibodi
use
immunotherapi
one
antibodi
human
anticea
antibodi
origin
develop
mice
bind
membranebound
cea
shown
vitro
studi
bind
enhanc
ceaspecif
cytotox
cea
human
colorect
cancer
cell
line
incub
human
pbmc
nk
cell
increas
fc
portion
antibodi
glycosyl
second
anticea
monoclon
labetuzumab
also
shown
induc
adcc
vitro
cea
colon
tumor
cell
inhibit
growth
lung
metastas
nude
mice
phase
iii
trial
pancreat
cancer
patient
complet
result
publish
pankomab
glycotop
germani
murin
antihuman
antibodi
bind
carbohydr
induc
conform
tumor
epitop
greatli
increas
tumor
specif
pankomab
induc
adcc
posit
cell
also
induc
death
follow
intern
inhibit
rna
polymeras
link
human
version
pankomab
shown
react
tumor
express
multipl
human
carcinoma
although
clinic
trial
publish
antibodi
know
herceptin
genetech
inc
ca
usa
trastuzumab
use
success
treat
pancreat
cancer
murin
model
treatment
trastuzumab
prolong
surviv
reduc
liver
metastasi
nude
mice
orthotop
challeng
human
pancreat
tumor
cell
line
express
low
level
pancreat
line
sensit
adcc
lysi
trastuzumab
vitro
similar
result
found
nude
mice
challeng
highexpress
human
pancreat
cancer
cell
line
treat
trastuzumab
combin
treatment
significantli
inhibit
tumor
growth
compar
either
treatment
alon
combin
matuzumab
antiegfr
antibodi
trastuzumab
treatment
result
inhibit
tumor
growth
nude
mous
model
pancreat
cancer
combin
treatment
fourtim
effect
treatment
either
antibodi
alon
group
also
found
combin
antibodi
treatment
effect
gemcitabin
treatment
orthotop
nude
mice
studi
number
clinic
trial
involv
trastuzumab
list
tabl
recent
year
much
work
focus
adopt
tumor
immunotherapi
patient
cell
expand
reinfus
patient
one
method
result
select
expans
cell
endogen
express
tcr
specif
tumor
antigen
interest
exampl
murin
ovarian
cancer
model
hung
et
al
vaccin
mice
murin
mesothelin
dna
prior
antigenspecif
tcell
expans
ex
vivo
mesothelinspecif
tcell
clone
transfer
tumorchalleng
mice
result
decreas
tumor
volum
increas
surviv
similarli
clinic
studi
autolog
cell
isol
patient
pbmc
expand
incub
cell
line
prior
administr
pancreat
cancer
patient
mean
surviv
time
unresect
patient
studi
month
howev
patient
resect
pancreat
cancer
surviv
rate
respect
mean
surviv
time
month
similar
studi
group
kondo
et
al
isol
adher
cell
patient
pbmc
gener
matur
dc
puls
peptid
puls
dc
administ
along
autolog
expand
cell
patient
unresect
recurr
pancreat
cancer
remark
complet
respons
observ
one
patient
lung
metastas
mean
surviv
time
whole
group
month
suggest
addit
puls
dc
may
improv
outcom
altern
antigenspecif
expans
transduct
patient
cell
usual
via
lentiviru
chimer
antigen
receptor
car
specif
tumor
antigen
receptor
transmembran
protein
typic
compris
antibodyderiv
singlechain
variabl
fragment
scfv
specif
tumor
antigen
fuse
hing
region
spacer
membran
span
element
signal
domain
often
intracellular
signal
domain
contain
signal
motif
multipl
molecul
chain
allow
tcr
costimulatori
signal
cascad
initi
lead
tcell
activ
result
cell
recogn
tumor
antigen
nativ
form
reli
present
antigen
mhc
highli
advantag
tumor
often
downregul
mhci
express
chimer
antigen
receptor
creat
specif
mesothelin
cea
carpenito
et
al
gener
car
recogn
mesothelin
via
scfv
util
intracellular
signal
domain
human
cell
express
receptor
transfer
tumor
bear
nodscid
mice
reduc
tumor
volum
observ
similar
result
gener
cell
express
car
possess
intracellular
motif
specif
human
cea
administ
cea
tumorchalleng
mice
addit
shirasu
et
al
gener
ceaspecif
car
util
human
monoclon
antibodi
cytoplasm
motif
express
jurkat
cell
ceacar
initi
signal
cascad
similar
expect
tcrmediat
activ
car
specif
also
gener
use
antibodi
intracellular
signal
motif
cell
express
car
prolifer
produc
cytokin
respons
antigen
challeng
kill
tumor
cell
vitro
delay
growth
tumor
mice
bakhtiari
et
al
develop
similar
car
intracellular
signal
motif
express
jurkat
cell
stimul
includ
cytokin
product
kill
cell
line
cell
express
car
chain
signal
motif
shown
produc
cytokin
lyse
breast
cancer
tumor
line
follow
antigen
stimul
mice
challeng
breast
cancer
tumor
longterm
tumorfre
surviv
administr
cell
found
develop
memori
respons
protect
rechalleng
tumor
likewis
cell
express
herceptinbas
car
signal
motif
shown
lyse
tumor
vitro
suppress
tumor
growth
vivo
murin
model
number
phase
clinic
trial
involv
carexpress
cell
current
recruit
breast
cancer
patient
although
process
result
larg
popul
antigenspecif
cell
adopt
immunotherapi
expens
time
consum
process
comparison
vaccin
antibodi
therapi
discuss
articl
publish
studi
util
car
express
cell
pancreat
cancer
murin
model
pancreat
cancer
despit
progress
vaccin
develop
increas
understand
basic
immun
mechan
clinic
applic
therapeut
cancer
vaccin
character
mani
setback
increas
awar
gap
knowledg
regard
tumorinduc
immun
suppress
other
shown
tumor
microenviron
pancreat
cancer
preferenti
favor
recruit
immun
suppressor
rather
immun
effector
cell
type
figur
pancreat
cancer
cell
activ
contribut
immun
suppress
product
immun
suppress
cytokin
eg
express
surfac
molecul
mediat
immun
suppress
eg
fasl
possibl
btla
addit
tumorassoci
macrophag
tam
tumorassoci
fibroblast
plasmacytoid
dendrit
cell
pdc
express
tryptophanconvert
enzym
dioxygenas
ido
treg
solubl
factor
produc
suppressor
cell
contribut
pancreat
cancerinduc
immun
suppress
final
recent
studi
describ
heterogen
popul
immatur
cell
aris
myeloid
lineag
term
myeloidderiv
suppressor
cell
mdsc
mdsc
express
myelomonocyticmacrophag
marker
granulocyticneutrophil
marker
report
immatur
statu
mdsc
demonstr
absenc
marker
termin
differenti
lin
dr
mdsc
differ
tam
pdc
fulli
differenti
lineag
cell
accumul
mdsc
patient
advanc
cancer
includ
pancreat
cancer
demonstr
close
relat
extent
diseas
correl
well
diseas
stage
instrument
shape
immunosuppress
environ
tumor
cell
tumorassoci
fibroblast
particular
secret
chemokin
cytokin
chemokin
induc
motil
endotheli
cell
tumor
cell
addit
leukocyt
subpopul
recruit
tumor
chemokin
skew
tumor
environ
toward
cell
support
tumor
growth
promot
angiogenesi
tumor
invas
metastasi
format
suppress
immun
effector
cell
exampl
recent
observ
treg
cell
tumor
microenviron
human
pancreat
adenocarcinoma
express
pancreat
tumor
cell
produc
greater
tenfold
higher
level
ligand
clear
evid
crosstalk
variou
suppressor
cell
subset
exampl
mdsc
promot
treg
recruit
mainten
independ
mechan
ido
product
tumorassoci
dc
macrophag
also
implic
treg
activ
expans
ido
express
induc
dc
revers
signal
respect
express
treg
turn
ido
activ
treg
induc
differenti
naiv
cell
toward
treg
convert
tryptophan
nformyl
kynurenin
effector
cell
depend
tryptophan
prolifer
inhibit
tam
mdsc
also
skew
tcell
subset
composit
toward
phenotyp
cytokin
interplay
variou
subset
suppressor
cell
cytokin
creat
power
barrier
immun
attack
make
progress
defin
molecular
pathway
immun
suppress
becom
relev
integr
strategi
activ
antitumor
immun
neutral
overcom
tumorinduc
immun
suppress
figur
immun
activ
strategi
multifacet
take
advantag
innat
adapt
immun
effector
mechan
target
immun
suppress
may
need
equal
comprehens
order
effect
preclin
studi
anim
tumor
model
provid
proofofconcept
target
immun
suppress
may
impact
cancer
vaccin
exampl
promis
antibodi
treatment
involv
use
aim
prevent
downregul
activ
cell
monotherapi
shown
encourag
result
small
percentag
patient
advanc
cancer
recent
complet
phase
iii
trial
antibodi
without
peptid
vaccin
significantli
prolong
surviv
patient
metastat
melanoma
interestingli
improv
peptid
vaccin
efficaci
reason
lack
addit
effect
clear
investig
studi
may
due
minim
clinic
activ
vaccin
although
disappoint
clinic
benefit
statist
signific
without
vaccin
support
idea
patient
exist
endogen
antitumor
immun
respons
use
may
enhanc
respons
induc
clinic
meaning
respons
time
unlik
monotherapi
lead
longterm
cure
major
patient
regard
recent
complet
phase
ii
trial
patient
local
advanc
metastat
pancreat
cancer
show
monotherapi
ineffect
patient
popul
likewis
commonli
use
strategi
neutral
pathway
via
antibodi
either
block
signal
neutral
first
clinic
studi
perform
antibodi
solid
tumor
hematolog
malign
experiment
drug
consist
fusion
protein
bind
cell
prevent
inhibitori
signal
yet
test
clinic
final
deplet
mdsc
murin
model
associ
improv
host
immun
respons
result
delay
tumor
growth
improv
surviv
increas
efficaci
vaccin
therapi
elimin
mdsc
shown
improv
antitumor
respons
restor
ctl
nk
function
decreas
tumor
angiogenesi
enhanc
immunotherapi
rather
describ
specif
strategi
detail
offer
comment
topic
conclud
current
knowledg
immun
suppressor
mechan
cancer
multipl
mechan
play
act
concert
exampl
product
certain
cytokin
restrict
individu
cell
type
thu
success
intervent
may
requir
multiprong
attack
heterogen
among
differ
histolog
type
tumor
regard
suppressor
mechan
present
domin
perhap
even
within
tumor
clinic
stage
histolog
type
obviou
implic
type
strategi
use
vaccin
selfantigen
associ
induct
treg
mdsc
exampl
nishikawa
et
al
report
immun
mice
plasmid
encod
tumor
antigen
result
mark
enhanc
vivo
tumor
growth
murin
pulmonari
metastasi
model
subsequ
analysi
find
reveal
deplet
treg
revers
effect
adopt
transfer
restor
suggest
vaccin
promot
prolifer
autoantigenreact
treg
similarli
tcell
clone
deriv
tumorinfiltr
lymphocyt
recent
describ
recogn
melanoma
antigen
characterist
treg
final
reiter
tumor
vaccin
may
effect
set
minim
diseas
ie
postsurgeri
time
tumorinduc
immun
suppress
like
also
minim
set
vaccin
induc
immunolog
memori
tumorspecif
cell
igg
antibodi
may
effect
howev
discuss
previous
patient
pancreat
cancer
advanc
diseas
time
diagnosi
candid
surgeri
ampl
evid
suggest
pancreat
cancer
induc
antitumor
immun
respons
also
ampl
evid
respons
enhanc
variou
immunebas
strategi
howev
success
clinic
applic
may
requir
better
understand
pancreat
cancer
evad
immun
recognit
integr
specif
strategi
target
immun
suppressor
mechan
review
current
statu
fdaapprov
immunebas
intervent
cancer
relev
ask
whether
futur
immun
therapi
treatment
prevent
cancer
recent
fda
approv
proveng
prime
exampl
consid
futur
optimist
sever
reason
first
understand
immun
mechan
acceler
past
decad
probabl
continu
includ
specif
knowledg
overcom
toler
self
tumor
antigen
implement
immunolog
adjuv
strategi
induc
immunolog
memori
combin
grow
emphasi
defin
molecular
pathway
immun
suppress
neg
regulatori
pathway
other
challeng
go
forward
near
futur
integr
everyth
learn
new
gener
vaccin
furthermor
expect
rapidli
evolv
techniqu
develop
sequenc
cancer
genom
unpreced
consequ
treatment
prevent
cancer
consid
monument
task
sever
year
ago
becom
routin
straightforward
assay
next
year
first
effort
alreadi
success
complet
pancreat
cancer
studi
demonstr
presenc
multipl
mutat
target
also
show
mani
mutat
alreadi
present
primari
pancreat
cancer
suggest
vaccin
primari
resect
may
protect
recurr
main
implic
immun
therapi
person
vaccin
longer
scienc
fiction
state
art
main
advantag
vaccin
tailor
toward
uniqu
mutat
found
patient
cancer
altern
appli
certain
subtyp
tumor
mutat
identifi
past
next
year
expect
sequenc
patient
cancer
normal
cell
part
diagnosi
immunolog
standpoint
immun
respons
mutat
nonself
antigen
much
robust
toler
antigen
minim
paper
special
note
highlight
tumor
environ
pancreat
cancer
highli
immunosuppress
increas
preval
multipl
type
suppressor
cell
key
treatment
patient
establish
diseas
integr
immun
strategi
neutral
immun
suppress
altern
vaccin
may
efficaci
administ
adjuv
therapi
immun
suppress
minim
prior
therapi
immunolog
milieu
character
high
level
immun
suppress
low
level
immun
respond
well
immunolog
memori
ideal
immun
therapi
augment
antigenspecif
immun
respons
also
reduc
immun
suppress
key
player
nk
cell
macrophag
b
cell
complement
cytokin
omit
increas
clariti
adcc
antibodydepend
cell
cytotox
mdsc
myeloidderiv
suppressor
cell
pc
pancreat
cancer
tabl
overview
candid
pancrea
cancerassoci
antigen
immun
target
ref
cell
surfac
gpilink
overexpress
glycoprotein
normal
express
oncofet
tissu
function
celladhes
molecul
first
tumor
antigen
describ
transmembran
overexpress
receptor
tyrosin
kinas
member
famili
involv
cell
growth
differenti
kra
intracellular
mutat
self
mutat
form
ra
gtpase
import
cell
prolifer
differenti
surviv
mesothelin
cell
surfac
gpilink
gpilink
glycoprotein
normal
express
surfac
mesotheli
cell
line
pleura
peritoneum
pericardium
low
level
bind
partner
transmembran
overexpress
hypoglycosyl
type
transmembran
glycoprotein
express
apic
surfac
ductal
glandular
epitheli
cell
low
level
extracellular
domain
polypeptid
core
multipl
tandem
repeat
amino
acid
intracellular
mutat
self
tumor
suppressor
regul
cell
cycl
normal
inhibit
survivin
transcript
level
initi
apoptosi
dna
damag
unrepair
survivin
intracellular
overexpress
member
iap
famili
inhibit
caspas
activ
found
human
tumor
fetal
tissu
complet
absent
termin
differenti
cell
telomeras
intracellular
overexpress
ribonucleoprotein
respons
rnadepend
synthesi
telomer
dna
tert
catalyt
subunit
transmembran
overexpress
tyrosin
kinas
member
platelet
deriv
growth
factor
famili
receptor
vegf
function
blood
vessel
develop
cea
carcinoembryon
antigen
gpi
glycosylphosphatidylinositol
iap
inhibitor
apoptosi
protein
muc
mucin
tert
telomeras
revers
transcriptas
vegfr
vegf
receptor
immunotherapi
author
manuscript
avail
pmc
februari
